BACKGROUND: A potential dual role of folate in colorectal cancer (CRC) is currently subject to debate. We investigate the associations between plasma folate, several relevant folate-related polymorphisms, and CRC risk within the large European Prospective Investigation into Cancer and Nutrition cohort. METHODS: In this nested case-control study, 1,367 incident CRC cases were matched to 2,325 controls for study center, age, and sex. Risk ratios (RR) were estimated with conditional logistic regression and adjusted for smoking, education, physical activity, and intake of alcohol and fiber. RESULTS: Overall analyses did not reveal associations of plasma folate with CRC. The RR (95% confidence interval; Ptrend) for the fifth versus the first quintile of folate status was 0.94 (0.74-1.20; 0.44). The polymorphisms MTHFR677C-->T, MTHFR1298A-->C, MTR2756A-->G, MTRR66A-->G, and MTHFD11958G-->A were not associated with CRC risk. However, in individuals with the lowest plasma folate concentrations, the MTHFR 677TT genotype showed a statistically nonsignificant increased CRC risk [RR (95% CI; Ptrend) TT versus CC=1.39 (0.87-2.21); 0.12], whereas those with the highest folate concentrations showed a nonsignificant decreased CRC risk [RR TT versus CC=0.74 (0.39-1.37); 0.34]. The SLC19A180G-->A showed a positive association with CRC risk [RR AA versus GG 1.30 (1.06-1.59); <0.01]. CONCLUSIONS: This large European prospective multicenter study did not show an association of CRC risk with plasma folate status nor with MTHFR polymorphisms. IMPACT: Findings of the present study tend to weaken the evidence that folate plays an important role in CRC carcinogenesis. However, larger sample sizes are needed to adequately address potential gene-environment interactions. Copyright (c) 2010 AACR
BACKGROUND: A potential dual role of folate in colorectal cancer (CRC) is currently subject to debate. We investigate the associations between plasma folate, several relevant folate-related polymorphisms, and CRC risk within the large European Prospective Investigation into Cancer and Nutrition cohort. METHODS: In this nested case-control study, 1,367 incident CRC cases were matched to 2,325 controls for study center, age, and sex. Risk ratios (RR) were estimated with conditional logistic regression and adjusted for smoking, education, physical activity, and intake of alcohol and fiber. RESULTS: Overall analyses did not reveal associations of plasma folate with CRC. The RR (95% confidence interval; Ptrend) for the fifth versus the first quintile of folate status was 0.94 (0.74-1.20; 0.44). The polymorphisms MTHFR677C-->T, MTHFR1298A-->C, MTR2756A-->G, MTRR66A-->G, and MTHFD11958G-->A were not associated with CRC risk. However, in individuals with the lowest plasma folate concentrations, the MTHFR 677TT genotype showed a statistically nonsignificant increased CRC risk [RR (95% CI; Ptrend) TT versus CC=1.39 (0.87-2.21); 0.12], whereas those with the highest folate concentrations showed a nonsignificant decreased CRC risk [RR TT versus CC=0.74 (0.39-1.37); 0.34]. The SLC19A180G-->A showed a positive association with CRC risk [RR AA versus GG 1.30 (1.06-1.59); <0.01]. CONCLUSIONS: This large European prospective multicenter study did not show an association of CRC risk with plasma folate status nor with MTHFR polymorphisms. IMPACT: Findings of the present study tend to weaken the evidence that folate plays an important role in CRC carcinogenesis. However, larger sample sizes are needed to adequately address potential gene-environment interactions. Copyright (c) 2010 AACR
Authors: D Leclerc; E Campeau; P Goyette; C E Adjalla; B Christensen; M Ross; P Eydoux; D S Rosenblatt; R Rozen; R A Gravel Journal: Hum Mol Genet Date: 1996-12 Impact factor: 6.150
Authors: J Chen; E Giovannucci; K Kelsey; E B Rimm; M J Stampfer; G A Colditz; D Spiegelman; W C Willett; D J Hunter Journal: Cancer Res Date: 1996-11-01 Impact factor: 12.701
Authors: J Ma; M J Stampfer; B Christensen; E Giovannucci; D J Hunter; J Chen; W C Willett; J Selhub; C H Hennekens; R Gravel; R Rozen Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-09 Impact factor: 4.254
Authors: I Kato; A M Dnistrian; M Schwartz; P Toniolo; K Koenig; R E Shore; A Akhmedkhanov; A Zeleniuch-Jacquotte; E Riboli Journal: Br J Cancer Date: 1999-04 Impact factor: 7.640
Authors: Archana Unnikrishnan; Tom M Prychitko; Hiral V Patel; Mahbuba E Chowdhury; Amanda B Pilling; Lisa F Ventrella-Lucente; Erin V Papakonstantinou; Diane C Cabelof; Ahmad R Heydari Journal: Free Radic Biol Med Date: 2010-11-08 Impact factor: 7.376
Authors: Todd M Gibson; Stephanie J Weinstein; Ruth M Pfeiffer; Albert R Hollenbeck; Amy F Subar; Arthur Schatzkin; Susan T Mayne; Rachael Stolzenberg-Solomon Journal: Am J Clin Nutr Date: 2011-08-03 Impact factor: 7.045
Authors: Marian L Neuhouser; Ting-Yuan David Cheng; Shirley A A Beresford; Elissa Brown; Xiaoling Song; Joshua W Miller; Yingye Zheng; Cynthia A Thomson; James M Shikany; Mara Z Vitolins; Thomas Rohan; Ralph Green; Cornelia M Ulrich Journal: Int J Cancer Date: 2015-02-24 Impact factor: 7.396
Authors: Eric D Ciappio; Zhenhua Liu; Ryan S Brooks; Joel B Mason; Roderick T Bronson; Jimmy W Crott Journal: Gut Date: 2011-06-09 Impact factor: 23.059
Authors: Jung Eun Lee; Esther K Wei; Charles S Fuchs; David J Hunter; I-Min Lee; Jacob Selhub; Meir J Stampfer; Walter C Willett; Jing Ma; Edward Giovannucci Journal: Cancer Causes Control Date: 2012-02-26 Impact factor: 2.506